The FDA has issued a complete response letter to the biologics license application seeking the approval of tabelecleucel for ...

Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated ...

During a Case-Based Roundtable® event, Jean A. Yared, MD, moderated a discussion on the approach to CAR T-cell therapy for a ...

The FDA has approved the investigational new drug application of 225Ac-SSO110, allowing for the start of a phase 1/2 trial in ...

Axatilimab has gained FDA approval in 9 mg and 22 mg vials, expanding treatment options for patients with chronic GVHD after ...

Evan Y. Yu, MD, discusses how community oncologists can critically weigh the evidence from studies on androgen deprivation ...

Christina Henson, MD, discussed some of the current imaging guidelines in head and neck cancer, with a focus on extranodal extension.

Evan Y. Yu, MD, discusses how safety data for first-line androgen deprivation therapy plus androgen receptor pathway inhibitors (ARPI) regimens such as darolutamide, abiraterone, enzalutamide, and ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in ...

Panelists discuss key learnings from recent studies on lower-risk myelodysplastic syndrome (LR-MDS) treatment, identify ...